No Data
No Data
GFS, PETS and CYTK Are Among After Hour Movers
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other...
Bank of America Securities Remains a Buy on Sana Biotechnology (SANA)
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results
Express News | HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target
Sana Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 61.18% HC Wainwright & Co. → $12 Reiterates Buy → Buy 03/01/2024 101.48% JMP Securities $8 → $1
No Data